サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1679434

ペプチド薬物複合体の市場規模、シェア、動向分析レポート：製品タイプ別、地域別、セグメント別予測、2025年～2030年

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ペプチド薬物複合体の市場規模、シェア、動向分析レポート：製品タイプ別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年02月28日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド薬物複合体市場の成長と動向

Grand View Research, Inc.の最新レポートによると、ペプチド薬物複合体の世界市場規模は2030年までに128億4,000万米ドルに達すると推定され、2025～2030年にかけて19.21%のCAGRで成長する見込みです。

市場成長の背景には、世界のがん患者の急増とそれに関連する死亡率、ペプチド薬物複合体（PDC）の強力な臨床検査パイプライン、低分子化学療法剤に関連する制御不能な毒性などの既存製品の関連副作用があります。

WHOによると、がんは疾病関連死亡の世界の主要原因です。2020年には、世界で約1,000万人、米国では600万人以上ががんによる死亡を記録しています。さらに、cancer.govによると、2040年までに年間の新規がん患者数は2,900万人に達し、がん関連死亡者数は1,600万人に達すると推定されています。したがって、制御不能な細胞増殖を標的とするPDCのような新規治療に対する需要の高まりが、ペプチド薬物複合体市場の成長を促進すると予想されます。

現在、Lutathera（Lu 177 dotatate）とPepaxto（Melflufen）は、制御不能な細胞増殖を治療するためにFDAが承認した2つのPDCです。市場には、成人のソマトスタチン受容体陽性胃腸膵神経内分泌腫瘍を適応症とするNovartisのルタセラ（ルテチウムLu 177）としてFDAが承認したPDCがあります。その後、2021年2月にOncopeptides ABsは、多発性骨髄腫の治療を適応とするPepaxto（メルファラン）のFDAによる早期承認を発表しました。この領域には限られたPDCしか存在しないため、成長には有益な機会があります。

さらに、強固な臨床検査パイプラインの存在と新規PDCの発売が予想され、予測期間中の市場成長を後押しするとみられます。これらの背景には、脳腫瘍を対象とした第3相臨床検査中のPDC ANG1005、肺がんを対象とした第2相臨床検査中のPDC BT5528とBT1718があります。CBX-12も小細胞肺がん治療を適応とする第2相PDC候補です。

主要企業は、共同研究、M&A、契約などの戦略的イニシアチブを金融投資とともに実施しており、これが市場成長を促進しています。例えば、2021年12月、Coherent BiopharmaとWuXi STAは、ペプチド薬物複合体を含む現在と将来の治療を開発するための戦略的パートナーシップ契約を発表しました。

ペプチド薬物複合体市場レポートのハイライト

  • 2024年は治療セグメントが産業を支配し、最も速い成長が予測されます。
  • プルビクトセグメントが2024年に42.52%の収益シェアで産業を支配し、予測期間中に最も速いCAGRを示すと予測されます。
  • 北米のペプチド薬物複合体市場は2024年に世界シェアの75.02%を占め、主導的地位を占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ペプチド薬物複合体市場の変数、動向、範囲

  • 親市場の展望
  • 補助市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ドーパミン作動薬分析ツール
    • ポーターの分析
    • PESTEL分析
  • パイプライン分析
    • フェーズ1
    • フェーズ2
    • フェーズ3

第4章 ペプチド薬物複合体市場：製品別、推定・動向分析

  • ペプチド薬物複合体市場：製品セグメントダッシュボード
  • ペプチド薬物複合体市場：製品変動分析、2024年と2030年
  • イルッチックス
  • プルヴィクト
  • ルタセラ
  • オクトレオスキャン
  • その他

第5章 ペプチド薬物複合体市場：タイプ別、推定・動向分析

  • ペプチド薬物複合体市場：タイプセグメントダッシュボード
  • ペプチド薬物複合体市場：タイプ変動分析、2024年と2030年
  • 治療
  • 診断

第6章 ペプチド薬物複合体市場：地域別、推定・動向分析

  • ペプチド薬物複合体の市場シェア、地域別、2024年と2030年、100万米ドル
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 参加者概要
  • 製品ベンチマーク
  • 企業市場シェア分析、2024年
  • 企業プロファイル
    • Novartis AG
    • AstraZeneca
    • Oncopeptides AB
    • Bicycle Therapeutics
    • Cybrexa
    • Angiochem Inc.
    • Soricimed Biopharma
    • Theratechnologies Inc.

第8章 結論

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 List of Parameters
  • Table 4 List of Distributors
  • Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
  • Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 15 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 21 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 25 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Denmark Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 31 Denmark Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 Sweden Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Sweden Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Norway Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Norway Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 40 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 42 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 44 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 45 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 46 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 47 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 48 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 49 Thailand Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 50 Thailand Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 52 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 53 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 55 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
  • Table 68 Kuwait Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide drug conjugates market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and type segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Peptide therapeutics market value, 2024 (USD billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Peptide Drug Conjugates market: Product outlook and key takeaways
  • Fig. 17 Peptide drug conjugates market: Product movement analysis
  • Fig. 18 Lutathera market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 OctreoScan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Illuccix market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Pluvicto market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Peptide drug conjugates market: Type outlook and key takeaways
  • Fig. 24 Peptide drug conjugates market: Type movement analysis
  • Fig. 25 Therapeutic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diagnostic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Peptide drug conjugates market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 U.S. peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Canada peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 Mexico peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 UK peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Germany peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 France peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Italy peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Spain peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Denmark peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Sweden peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Norway peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Japan peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 China peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 India peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Australia peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Thailand peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 South Korea peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Brazil peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Argentina peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 South Africa peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 UAE peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Kuwait peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Company/competition categorization
  • Fig. 85 Company market share analysis, 2024
  • Fig. 86 Strategy mapping
目次
Product Code: GVR-4-68040-001-8

Peptide Drug Conjugates Market Growth & Trends:

The global peptide drug conjugates market size is estimated to reach USD 12.84 billion by 2030, registering to grow at a CAGR of 19.21% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis's Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA's accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights:

  • The therapeutic segment dominated the industry in 2024 and is anticipated to witness the fastest growth.
  • The pluvicto segment dominated the industry with a revenue share of 42.52% in 2024 and is expected to exhibit the fastest CAGR over the forecast period.
  • North America peptide drug conjugates market held a leading position in 2024, accounting for 75.02% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market drivers analysis
      • 3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
      • 3.3.1.2. Robust clinical trial pipeline
      • 3.3.1.3. Growing focus on targeted drug delivery
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Long R&D time and slow clinical development process
      • 3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC's)
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis

  • 4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
  • 4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Illuccix
    • 4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Pluvicto
    • 4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lutathera
    • 4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. OctreoScan
    • 4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis

  • 5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
  • 5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Therapeutics
    • 5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Diagnostics
    • 5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis

  • 6.1. Peptide Drug Conjugates Market Share, By Region, 2024 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target Disease Prevalence
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Reimbursement Framework
      • 6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Reimbursement Framework
      • 6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Reimbursement Framework
      • 6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Framework
      • 6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Framework
      • 6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Reimbursement Framework
      • 6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Reimbursement Framework
      • 6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Reimbursement Framework
      • 6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Reimbursement Framework
      • 6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Reimbursement Framework
      • 6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Reimbursement Framework
      • 6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Framework
      • 6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Framework
      • 6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Framework
      • 6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Participant Overview
  • 7.4. Financial Performance
  • 7.5. Product Bench Marking
  • 7.6. Company Market Share Analysis, 2024
  • 7.7. Company Profiles
    • 7.7.1. Novartis AG
      • 7.7.1.1. Participant's Overview
      • 7.7.1.2. Financial Performance
      • 7.7.1.3. Product Benchmarking
      • 7.7.1.4. Recent Developments/ Strategic Initiatives
    • 7.7.2. AstraZeneca
      • 7.7.2.1. Participant's Overview
      • 7.7.2.2. Financial Performance
      • 7.7.2.3. Product Benchmarking
      • 7.7.2.4. Recent Developments/ Strategic Initiatives
    • 7.7.3. Oncopeptides AB
      • 7.7.3.1. Participant's Overview
      • 7.7.3.2. Financial Performance
      • 7.7.3.3. Product Benchmarking
      • 7.7.3.4. Recent Developments/ Strategic Initiatives
    • 7.7.4. Bicycle Therapeutics
      • 7.7.4.1. Participant's Overview
      • 7.7.4.2. Financial Performance
      • 7.7.4.3. Product Benchmarking
      • 7.7.4.4. Recent Developments/ Strategic Initiatives
    • 7.7.5. Cybrexa
      • 7.7.5.1. Participant's Overview
      • 7.7.5.2. Financial Performance
      • 7.7.5.3. Product Benchmarking
      • 7.7.5.4. Recent Developments/ Strategic Initiatives
    • 7.7.6. Angiochem Inc.
      • 7.7.6.1. Participant's Overview
      • 7.7.6.2. Financial Performance
      • 7.7.6.3. Product Benchmarking
      • 7.7.6.4. Recent Developments/ Strategic Initiatives
    • 7.7.7. Soricimed Biopharma
      • 7.7.7.1. Participant's Overview
      • 7.7.7.2. Financial Performance
      • 7.7.7.3. Product Benchmarking
      • 7.7.7.4. Recent Developments/ Strategic Initiatives
    • 7.7.8. Theratechnologies Inc.
      • 7.7.8.1. Participant's Overview
      • 7.7.8.2. Financial Performance
      • 7.7.8.3. Product Benchmarking
      • 7.7.8.4. Recent Developments/ Strategic Initiatives

Chapter 8. Conclusion